Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: Addict Neurosci. 2023 May 18;7:100103. doi: 10.1016/j.addicn.2023.100103

Table 1.

Compounds that have been shown to alter behaviors relevant to nicotine seeking in laboratory animals.

Compound Mechanism of Action Behavioral findings in animal models Citation
Naltrexone/naloxone MOR antagonist Naloxone produced a conditioned place aversion in rats chronically treated with nicotine. [20]
SB-334,867 Hypocretin receptor 1 antagonist SB-334,867 decreased nicotine self-administration in rats; pre-treatment with SB-334,867 blocked hypocretin-induced and cue-induced reinstatement of nicotine seeking behavior. [21–23]
LY314582 mGluR2 agonist Infusion into the VTA of nicotine-dependent rats precipitated withdrawal-like increases in ICSS reward threshold. [24–26]
AZD8418, AZD8529 mGluR2 PAMs Decreased nicotine self-administration and cue-induced reinstatement of nicotine-seeking behavior in rats. [27,28]
MPEP mGluR5 NAM Decreased nicotine self-administration and reinstatement of nicotine-seeking behavior. [29–31]
CGP44532 GABAB receptor agonist Decreased nicotine self-administration in rats. [32,33]
CGP7930, BHF177, GS39783, KK-92A GABAB receptor PAMs Attenuated nicotine-self administration and cue-induced nicotine-seeking behavior. [32,34,35]
Clofibrate PPARα agonist Clofibrate abolished nicotine self-administration in both naïve rats and those with a history of self-administering nicotine. [36]
Pioglitazone PPARγ agonist Pioglitazone attenuated somatic and affective symptoms of nicotine withdrawal in rats and mice. [37]